Patent · US Active

RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

US9260471B2 · kind B2 · utility

51Cited by

155References

53Claims

0Family size

Assignee

Sirna Therapeutics, Inc. · US

Inventors

Mark Cancilla · Philadelphia, US
James J. Cunningham · Devon, US
Michael W. Flanagan · Menlo Park, US
Henry J. Haringsma · San Francisco, US
Denise M. Kenski · San Francisco, US
Matthew G. Stanton · Marlton, US
Steven M. Stirdivant · Cary, US
Aarron T. Willingham · San Francisco, US

Key dates

Filing date	Oct 25, 2011
Grant date	Feb 16, 2016
Priority date	—
Expiry date	Oct 25, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/51
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.